Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PepGen Inc. (PEPG)

PepGen posts updated corporate presentation for May 26-30 myotonic dystrophy conference

Neutral Impact 2 of 5 other Written later

PepGen Inc. updated its corporate presentation on May 21, 2026, ahead of its participation in the 15th International Myotonic Dystrophy Consortium, May 26-30, 2026. The filing contains no new financial results, and it reiterates the company's timelines for clinical data from its FREEDOM2 trial, which the presentation says is subject to a partial clinical hold placed by the U.S. FDA.

Key points

  • Company expects FREEDOM2 10 mg/kg clinical results in 2H 2026 and 12.5 mg/kg clinical results in 2027.
  • Presentation states cash runway into 2H 2027.
  • Presentation notes the U.S. FDA recently placed a partial clinical hold on the FREEDOM2 study.
  • Presentation cites 13 patients enrolled in the FREEDOM-OLE at 5 mg/kg, including 6 from FREEDOM2.

The filing

CompanyPepGen Inc. (PEPG)
Form8-K, current report
Filed with the SECMay 21, 2026, 7:30 AM ET
Accession number0001193125-26-233403

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.